Literature DB >> 16116021

Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporal membrane oxygenation.

Corinna Velik-Salchner, Consolato Sergi, Dietmar Fries, Patrizia Moser, Werner Streif, Christian Kolbitsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16116021     DOI： 10.1213/01.ANE.0000173666.80578.49

Source DB:  PubMed          Journal:  Anesth Analg        ISSN： 0003-2999            Impact factor:   5.108


× No keyword cloud information.
  4 in total

1.  Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.

Authors:  C N Dang; L I Katakam; P B Smith; C M Cotten; R N Goldberg; N Chandler; C D Thornburg; M Bidegain
Journal:  J Perinatol       Date:  2010-07-29       Impact factor: 2.521

2.  Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage.

Authors:  Yoan Lamarche; Philippe Demers; Nancy C Poirier; Danielle Robitaille; Raymond Cartier
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

Review 3.  Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children.

Authors:  Madhuradhar Chegondi; Niranjan Vijayakumar; Balagangadhar R Totapally
Journal:  Pediatr Rep       Date:  2022-07-11

Review 4.  Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review.

Authors:  Xavier Repessé; Siu Ming Au; Nicolas Bréchot; Jean-Louis Trouillet; Pascal Leprince; Jean Chastre; Alain Combes; Charles-Edouard Luyt
Journal:  Crit Care       Date:  2013-03-25       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.